Terns Pharmaceuticals Inc
$ 41.45
1.44%
24 Feb - close price
- Market Cap 4,444,231,000 USD
- Current Price $ 41.45
- High / Low $ 41.52 / 39.83
- Stock P/E N/A
- Book Value 3.25
- EPS -1.02
- Next Earning Report 2026-03-19
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.20 %
- ROE -0.29 %
- 52 Week High 48.26
- 52 Week Low 1.86
About
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of nonalcoholic steatohepatitis (NASH) and other chronic liver diseases. The company is headquartered in Foster City, California.
Analyst Target Price
$58.11
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-10 | 2025-08-05 | 2025-05-12 | 2025-03-12 | 2024-11-12 | 2024-08-05 | 2024-05-13 | 2024-03-14 | 2023-11-14 | 2023-08-08 | 2023-05-15 | 2023-03-27 |
| Reported EPS | -0.27 | -0.26 | -0.26 | -0.24 | -0.28 | -0.31 | -0.3 | -0.29 | -0.42 | -0.25 | -0.31 | -0.29 |
| Estimated EPS | -0.3021 | -0.2918 | -0.2702 | -0.3002 | -0.32 | -0.34 | -0.34 | -0.29 | -0.31 | -0.34 | -0.27 | -0.43 |
| Surprise | 0.0321 | 0.0318 | 0.0102 | 0.0602 | 0.04 | 0.03 | 0.04 | 0 | -0.11 | 0.09 | -0.04 | 0.14 |
| Surprise Percentage | 10.6256% | 10.8979% | 3.775% | 20.0533% | 12.5% | 8.8235% | 11.7647% | 0% | -35.4839% | 26.4706% | -14.8148% | 32.5581% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-19 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.29 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TERN
2026-02-23 17:01:38
Investors looking to buy Terns Pharmaceuticals Inc (TERN) shares but hesitant about the current market price of $39.66, could consider selling a January 2028 put option at the $30 strike. This strategy offers a potential 34% return on the $30 commitment, translating to a 17.8% annualized rate of return, by collecting a premium of $10.20 per share. The put seller only acquires shares if the stock drops below $30, resulting in a cost basis of $19.80 (before commissions), otherwise, they profit from the collected premium.
2026-02-16 21:57:30
Wall Street analysts project a 50.91% upside for Terns Pharmaceuticals (TERN). This article examines the stock's recent performance, analyst ratings, and factors that could influence its future price movement. Investors are interested if the company can reach this high target.
2026-02-14 20:57:42
This article analyzes the potential upside for Terns Pharmaceuticals (TERN) as predicted by Wall Street analysts. With an average price target suggesting a 50.91% increase, the report will likely delve into the factors contributing to this optimistic forecast. It aims to assess whether the stock can genuinely achieve such a significant surge based on current market conditions and company performance.
2026-02-09 19:57:54
Leerink Partners initiated coverage on Terns Pharmaceuticals (NASDAQ:TERN) with an "outperform" rating and a $58.00 price target, suggesting a 53.7% upside. The broader analyst consensus for TERN stock is a "Moderate Buy" with an average price target of $55.80. Notable insider selling from CEO Amy Burroughs and other insiders has been observed, with a total of 141,243 shares worth $5.31 million sold in the last 90 days.
2026-02-09 11:59:31
Leerink Partners has initiated coverage on Terns Pharmaceuticals (NASDAQ:TERN) with an Outperform rating and a $58.00 price target, citing potential upside of 61%. The firm highlights TERN-701, an investigational drug for chronic myeloid leukemia, as a significant value driver with a potential $4.8 billion opportunity in the frontline setting. This comes after Terns Pharmaceuticals raised $747.5 million through a public offering and amended a license agreement for TERN-701.
2026-02-09 11:58:55
Leerink Partners has initiated coverage on Terns Pharmaceuticals (NASDAQ:TERN) with an Outperform rating and a price target of $58.00, citing the potential of its drug candidate TERN-701 for chronic myeloid leukemia (CML). The drug, which is a next-generation allosteric BCR::ABL1 inhibitor, shows promise with early Phase 1 data suggesting a best-in-class profile and a clean safety record. Other recent developments include a successful public offering and strong analyst interest, with some firms setting even higher price targets.
